

Original Article

Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study


Hans Hauner^a Ljiljana Hastreiter^a Dieter Werdier^b Annette Chen-Stute^c Jürgen Scholze^d Matthias Blüher^e

^aElse Kröner-Fresenius-Center for Nutritional Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; ^bSAM GmbH, Aachen, Germany; ^cAdipositas-Zentrum Oberhausen, Oberhausen, Germany; ^dCentrum für Innere Medizin, Medizinische Polyklinik, Charité-Universitätsmedizin, Berlin, Germany; ^eDepartment of Medicine, University of Leipzig, Leipzig, Germany

Supplemental Material

Hauner et al.: Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study

Supplementary figure



Supplementary. fig. 1. Weight changes during and after 24 weeks of active therapy

Supplementary table 1. HADS subscores at baseline, after 24 weeks of treatment (24 weeks) and 4 weeks after end of treatment (+ 4 weeks)

	Treatment	timepoint	ITT		p value
			N	N (missing) mean (SD)	
Anxiety	Placebo	screening	56	3 2.9 (2.4)	0.636
		24 weeks	33	26 3.0 (3.1)	
		+ 4 weeks	42	17 2.4 (2.5)	
	16 mg	screening	56	1 3.0 (2.2)	0.0616
		24 weeks	42	15 2.3 (2.6)	
		+ 4 weeks	43	14 2.3 (2.9)	
	32 mg	screening	59	2 2.9 (2.1)	0.149
		24 weeks	45	16 2.4 (2.3)	
		+ 4 weeks	49	12 3.0 (3.2)	
	53.3 mg	screening	59	1 2.8 (2.0)	0.014
		24 weeks	48	12 2.2 (2.5)	
		+ 4 weeks	52	8 2.3 (3.0)	
	Total	screening	230	7 3.0 (2.2)	0.0129
		24 weeks	168	69 2.4 (2.6)	
		+ 4 weeks	186	51 2.5 (2.9)	
Depression	Placebo	screening	57	2 2.9 (2.4)	0.0332
		24 weeks	33	26 2.0 (2.5)	
		+ 4 weeks	42	17 2.2 (2.4)	
	16 mg	screening	56	1 2.8 (2.4)	0.002
		24 weeks	42	15 1.5 (2.3)	
		+ 4 weeks	43	14 1.5 (2.4)	
	32 mg	screening	59	2 2.8 (2.5)	0.0203
		24 weeks	44	17 1.7 (2.3)	
		+ 4 weeks	48	13 2.1 (2.7)	
	53.3 mg	screening	58	2 2.5 (2.4)	<0.0001
		24 weeks	48	12 1.1 (2.1)	
		+ 4 weeks	52	8 1.5 (2.9)	
	Total	screening	230	7 2.8 (2.4)	<0.0001
		24 weeks	167	70 1.6 (2.3)	
		+ 4 weeks	185	52 1.8 (2.6)	

HADS: Hospital Anxiety and Depression Scale

Mood disorders were determined by the 14-items HADS questionnaire.

All groups showed statistically significant reductions in the HADS depression subscore after 24 weeks most pronounced in the 53.3 mg group.

Hauner et al.: Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study